This article was originally published in The Rose Sheet
Executive SummaryFirst quarter fragrance sales decline 1.8% in Swiss Francs, or .3% in local currencies to $214.5 mil. (1 CHF=$0.77) due to discontinued sales of commodity ingredients, firm reports. Fine fragrances, however, experienced double-digit growth in local currencies driven by the launches of several prestige fragrances. Total sales in the quarter grew 2.4% in Swiss Francs, or 4.1% in local currencies, to $540.5 mil. Givaudan will continue to focus on developing proprietary fragrance ingredients this year, the company said during its annual investor meeting April 8. Among the exclusive ingredients Givaudan plans to launch is Toscanol, a replacement for Estragole, which has been found to be a naturally occurring genotoxic carcinogen. The company also will introduce Javanol, a sandalwood odorant at the World Perfumery Congress June 1-5 in Cannes, France, according to Givaudan Head of Fragrance Chemistry Markus Gautschi...
You may also be interested in...
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.